The Fibrinogen Deficiency (Factor I Deficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fibrinogen Deficiency (Factor I Deficiency). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Fibrinogen Deficiency (Factor I Deficiency) by five companies/universities/institutes. The top development phase for Fibrinogen Deficiency (Factor I Deficiency) is phase iii with four drugs in that stage. The Fibrinogen Deficiency (Factor I Deficiency) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Fibrinogen Deficiency (Factor I Deficiency) pipeline products market are: Biotest, Octapharma and Sinopharm Group.
The key targets in the Fibrinogen Deficiency (Factor I Deficiency) pipeline products market include Fibrinogen (Coagulation Factor I or FG).
The key mechanisms of action in the Fibrinogen Deficiency (Factor I Deficiency) pipeline product include Fibrinogen (Coagulation Factor I or FG) Replacement with four drugs in Phase III. The Fibrinogen Deficiency (Factor I Deficiency) pipeline products include three routes of administration with the top ROA being Intravenous and three key molecule types in the Fibrinogen Deficiency (Factor I Deficiency) pipeline products market including Blood Derivative, and Protein.
Fibrinogen Deficiency (Factor I Deficiency) overview
Fibrinogen deficiency (Factor I deficiency), is a rare inherited bleeding condition due to bi-allelic mutations in one of the three fibrinogen genes FGA, FGB and FGG; these encode α, β and γ fibrinogen polypeptides, respectively, which are folded together to form the mature fibrinogen hexameric structure. Mutations in the fibrinogen genes either affect the quantity of circulating fibrinogen (as in afibrinogenemia or hypofibrinogenemia) or the quality of fibrinogen (as in dysfibrinogenemia
For a complete picture of Fibrinogen Deficiency (Factor I Deficiency)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
